Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Sagimet Biosciences Inc. holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action, which serves as the primary focus of the company's active legal efforts at the patent office. This single action is under the review of 1 distinct examiner, BORALSKY, LUKE ALAN. As the busiest examiner for the portfolio, BORALSKY, LUKE ALAN is tasked with 1 busiest examiner pending action, which accounts for the total volume of the company's current prosecution.
The prosecution is conducted within 1 distinct art unit, reflecting a narrow technical specialization for the company's pending intellectual property in the Biotechnology & Pharmaceuticals field. For a practitioner, this concentration indicates that the success of the 1 pending office action is tied to the specific examination standards of a single art unit and the individual judgment of BORALSKY, LUKE ALAN. There is no examiner or art unit variety to mitigate the impact of this single point of review. The 1 distinct examiner and 1 distinct art unit together define the entire landscape for the company's current interaction with the patent office regarding its pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORALSKY, LUKE ALAN | 1 | 66.7% | +44.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18535291 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | BORALSKY, LUKE ALAN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18535291 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | BORALSKY, LUKE ALAN | 1624 | §103DP | Non-Final OA | — | Pending | Dec 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSagimet Biosciences Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Luke Alan Boralsky has the most, with 1 of Sagimet Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
